In this article, we will list the 5 Best Momentum Stocks to Buy According to Analysts. Please visit 10 Best Momentum Stocks to Buy According to Analysts if you would like to see the extended list and the methodology behind it.
5. CoreWeave, Inc. (NASDAQ:CRWV)
Analyst Upside: 32.71%
CoreWeave, Inc. (NASDAQ:CRWV) is one of the best momentum stocks to buy according to analysts. Citi lifted the price target on CoreWeave, Inc. (NASDAQ:CRWV) to $158 from $155 on May 14, maintaining a Buy rating on the shares. CoreWeave, Inc. (NASDAQ:CRWV) also received a rating update from DA Davidson on May 18. The company was downgraded to Neutral from Buy, with the firm bringing the price target on the stock down to $100 from $175 after assuming coverage of the name. DA Davidson told investors that it is“optimistic” on the outlook for compute, and believes that CoreWeave, Inc. (NASDAQ:CRWV) has made itself a key participant. However, the firm is also “skeptical” of the company’s ability to generate sufficient returns, given its margin profile and high dependence on debt financing.
In a separate development, CoreWeave, Inc. (NASDAQ:CRWV) announced on May 14 CoreWeave Sandboxes, which is an execution layer that offers AI researchers and platform teams isolated and secure environments to run agent tool use, reinforcement learning, and model evaluation. The company stated that the offering is available on a customer’s own CoreWeave infrastructure or as a serverless runtime through Weights & Biases (W&B).
CoreWeave, Inc. (NASDAQ:CRWV) is a cloud infrastructure technology company that offers the CoreWeave Cloud Platform, an integrated solution purpose-built for running AI workloads such as model training and inference.
4. Onto Innovation Inc. (NYSE:ONTO)
Analyst Upside: 33.46%
Onto Innovation Inc. (NYSE:ONTO) is one of the best momentum stocks to buy according to analysts. Onto Innovation Inc. (NYSE:ONTO) received several rating updates following the release of financial results for fiscal Q1. Jefferies lifted the price target on Onto Innovation Inc. (NYSE:ONTO) to $350 from $325 on May 7, maintaining a Buy rating on the shares. The firm told investors in a post-earnings note that the base business in HBM and CoWoS is continuing to see upside, while new opportunities are starting to layer in.
Onto Innovation Inc. (NYSE:ONTO) also received a rating update from Oppenheimer the same day. The firm lifted the price target on the stock to $370 from $350, maintaining an Outperform rating on the shares and stating that the company had already pre-announced stronger-than-expected Q1/Q2 guidance last month. Therefore, while it was never positioned for a big “beat,” it still had positive surprises. Oppenheimer further stated that the stock was down after hours on reflexive profit-taking after 93% year-to-date, but the firm would not over-read the reaction and anticipates investor attention to quickly refocus on strengthening fundamentals.
Onto Innovation Inc. (NYSE:ONTO) is involved in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The company is also involved in offering process and yield management solutions used in bare silicon wafer production and wafer processing facilities.
3. Cytokinetics, Incorporated (NASDAQ:CYTK)
Analyst Upside: 35.17%
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the best momentum stocks to buy according to analysts. Citi initiated coverage of Cytokinetics, Incorporated (NASDAQ:CYTK) with a Buy rating on May 18, setting a price target of $99. The firm named the stock a top pick among small-to-mid cap biotech stocks, and told investors that it is “bullish” on the Myqorzo launch in obstructive hypertrophic cardiomyopathy. It sees its optionality in nonobstructive disease as “still underappreciated”, adding that the fuller Phase 3 ACACIA-HCM data are expected to drive mid-term upside.
Cytokinetics, Incorporated (NASDAQ:CYTK) also received a rating update from Wells Fargo on May 7. The firm lifted the price target on the stock to $105 from $95 and maintained an Overweight rating on the shares, noting that fiscal Q1 Myqorzo sales point towards strong uptake in the initial 9 weeks of launch. This holds especially true with community cardiologists, according to the firm’s estimate. Wells anticipates momentum in obstructive hypertrophic cardiomyopathy to continue, and sees synergy with non-obstructive hypertrophic cardiomyopathy after ACACIA success.
Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company that discovers, develops, and commercializes muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The company’s clinical-stage drug candidates include omecamtiv mecarbil, CK-136, reldesemtiv, aficamten, and CK-3772271.
2. ImmunityBio Inc. (NASDAQ:IBRX)
Analyst Upside: 66.20%
ImmunityBio Inc. (NASDAQ:IBRX) is one of the best momentum stocks to buy according to analysts. ImmunityBio Inc. (NASDAQ:IBRX) announced on May 19 that the U.S. Food and Drug Administration accepted for review the supplemental Biologics License Application for ANKTIVA® in combination with Bacillus Calmette-Guerin to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary disease without carcinoma in situ. Management stated that the FDA assigned a PDUFA target action date of January 6, 2027, and that the supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary disease.
In a separate development, ImmunityBio Inc. (NASDAQ:IBRX) received a rating update from BTIG following the release of financial results for fiscal Q1. The firm cut the price target on the stock to $12 from $13, maintaining a Buy rating on the shares. It also reaffirmed the $44.2M in ANKTIVA sales pre-announced last month, which was up 15% q/q and 168% y/y.
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.
1. Aurora Innovation, Inc. (NASDAQ:AUR)
Analyst Upside: 69.73%
Aurora Innovation, Inc. (NASDAQ:AUR) is one of the best momentum stocks to buy according to analysts. Morgan Stanley lifted the price target on Aurora Innovation, Inc. (NASDAQ:AUR) to $14 from $12 on May 7, reiterating an Overweight rating on the shares.
In a separate development, Aurora Innovation, Inc. (NASDAQ:AUR) announced on May 13 the start of autonomous freight operations in Texas by Volvo Autonomous Solutions and DSV, with the first commercial truckload hauled using the Volvo VNL Autonomous.
The initiative aims at expanding to additional lanes over time, with the Volvo VNL Autonomous built for deployment in long-haul freight operations and integrated with the Aurora Driver. Management stated that V.A.S. is launching autonomous transport services for DSV between Aurora’s terminals in Dallas and Houston. A safety driver will be present in the vehicle during the initial phase, which is in line with Volvo’s current operational mode. It further stated that through the collaboration, DSV and V.A.S. aim to bolster day-to-day performance and build operational experience to support expansion to additional routes.
Aurora Innovation, Inc. (NASDAQ:AUR) is involved in the design and development of automobile hardware, software, and the provision of data services. Its offerings include the Aurora Driver, which allows a vehicle to drive itself.
While we acknowledge the potential of AUR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AUR and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
